• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

德国的抗高血压治疗,进行了成本效益分析。

Antihypertensive treatment in Germany, subjected to a cost-effectiveness analysis.

作者信息

Laaser U, Wenzel H

机构信息

University of Bielefeld, W. Germany.

出版信息

J Hum Hypertens. 1990 Aug;4(4):436-40.

PMID:2124267
Abstract

German physicians are increasingly adopting national and international recommendations on the promotion of non-pharmacological treatment of elevated blood pressure. This reflects a greater sensibility to the advantages and disadvantages of antihypertensive drugs versus dietary means. Furthermore, the rapid growth of health expenditure is a central issue in many policy decisions. Increasingly, the use of cost-effectiveness analysis (CEA) and cost-benefit analysis (CBA) is being advocated as a possible means of making the medical care system more efficient. We report an analysis of the value of treating hypertension in Germany-West.

摘要

德国医生越来越多地采用国内和国际上关于推广高血压非药物治疗的建议。这反映出对降压药物与饮食方法优缺点有了更高的敏感性。此外,医疗支出的快速增长是许多政策决策中的核心问题。越来越多的人主张使用成本效益分析(CEA)和成本效益分析(CBA)作为提高医疗保健系统效率的一种可能手段。我们报告了对德国西部高血压治疗价值的分析。

相似文献

1
Antihypertensive treatment in Germany, subjected to a cost-effectiveness analysis.德国的抗高血压治疗,进行了成本效益分析。
J Hum Hypertens. 1990 Aug;4(4):436-40.
2
The value of antihypertensive drugs: a perspective on medical innovation.抗高血压药物的价值:医学创新视角
Health Aff (Millwood). 2007 Jan-Feb;26(1):97-110. doi: 10.1377/hlthaff.26.1.97.
3
Cost-benefit and cost-effectiveness analysis of drug therapy.药物治疗的成本效益分析和成本效果分析。
Am J Hosp Pharm. 1985 Apr;42(4):791-802.
4
A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness.德国的一项全国性高血压治疗计划及其对成本、预期寿命和成本效益的估计影响。
Health Policy. 2007 Oct;83(2-3):257-67. doi: 10.1016/j.healthpol.2007.01.003. Epub 2007 Mar 1.
5
Economic costs and benefits of treating mild hypertension: results from a cross-sectional model.
N Z Med J. 1988 Oct 12;101(855):623-5.
6
Is the pharmacological treatment of mild to moderate hypertension cost effective in stroke prevention?轻度至中度高血压的药物治疗在预防中风方面是否具有成本效益?
N Z Med J. 1988 Apr 13;101(843):167-71.
7
Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level.南非高血压指南的成本效益分析:绝对风险与血压水平
Circulation. 2005 Dec 6;112(23):3569-76. doi: 10.1161/CIRCULATIONAHA.105.535922.
8
Cost-benefit of treating hypertension.
J Hypertens Suppl. 1994 Dec;12(10):S65-70.
9
Multivariate cost-effectiveness analysis: an application to optimizing ambulatory care for hypertension.
Inquiry. 1995 Fall;32(3):320-31.
10
Cost-effectiveness of the introduction of home blood pressure measurement in patients with office hypertension.对诊室高血压患者引入家庭血压测量的成本效益分析
J Hypertens. 2008 Apr;26(4):685-90. doi: 10.1097/HJH.0b013e3282f42285.

引用本文的文献

1
A review of cost-effectiveness analyses of hypertension treatment.高血压治疗的成本效益分析综述。
Pharmacoeconomics. 1992 Apr;1(4):250-64. doi: 10.2165/00019053-199201040-00003.
2
Cost-effectiveness of antihypertensive treatment: metoprolol versus thiazide diuretics.抗高血压治疗的成本效益:美托洛尔与噻嗪类利尿剂的比较。
Pharmacoeconomics. 1993 Jan;3(1):36-44. doi: 10.2165/00019053-199303010-00005.